Our Team
Our team consists of highly experienced and motivated professionals, who are all experts in their field. With many years of experience in the industry, they have the expertise to provide comprehensive services to our clients.
Mark Rampy, PhD, MBA
CEO, Co-Founder
An experienced industry leader with 25+ years of research, development, business development, and executive leadership experience (Human Genome Sciences, Inc., CoGenesys Inc, Teva, a multiple start-up companies). Dr. Rampy has a proven track record of building and growing companies focused on advancing new therapeutics in oncology and immunology and has taken multiple cutting-edge technologies from the laboratory into clinical trials.
Dr. Carol Nacy
COO, Co-Founder
A seasoned scientist-executive with extensive experience in discovery, development, and commercialization of drugs in oncology, immunology, and infectious diseases. Dr. Nacy successfully filed 4 INDs, developed products from concept to late-stage clinical trials, and managed a dozen clinical trials ranging from Phase 1 to pivotal trials in the US, Africa, and Russia. She has started and scaled early-stage pharma companies with a focus on investor liquidity (M&A, IPO). She has 170 scientific publications, several patents, raised over $180M in grant support and over $350M in investment in her various companies and nonprofits.
Dr. Stephen Wolpe
CSO, Co-Founder
An experienced scientist/entrepreneur who discovered the chemokine family while at Rockefeller University and generated one of the first monoclonal antibodies to TNF (the target of drugs like Humira). At Genetics Institute (now part of Pfizer), he led projects in oncology, inflammatory diseases, and stem cell biology. He then led research teams supporting therapeutics, diagnostics, biologics, vaccines, and ophthalmics at the Wellstat family group of privately held biopharmaceutical companies. He has worked with numerous companies in the US, Europe and Asia as a private consultant and mentors SBIR companies as an Entrepreneur-in-Residence for the National Institutes of Health (NIH). Dr. Wolpe worked on multiple IND filings and Ph1/Ph2 submissions for small molecules, immune-oncology products, and cell therapies.
Iftach Michaeli
CFO, Co-Founder
An experienced business executive with over 20 yrs experience. Iftach has a great record of starting and growing private companies. He oversaw the acquisition of Divosta Homes by the Pulte group and controlled and managed several construction development projects.
Rachel Nechushtai
D.Sc
Scientific Co-Founder Professor at the Hebrew University and the discoverer of the NAF-1-based peptide drugs in collaboration with Prof. Assaf Friedler. She is a world leader in the study of CISD/NEET proteins in cancer and an expert structural biologist with broad experience in studying cancer metabolism and signaling using in vitro and in vivo approaches. Prof. Nechushtai served as a consultant to BIOMEDICOM, and was a part of an approved BIRDF project.
Ron Elber, PhD
Scientific Co-Founder
A W.A. "Tex" Moncrief Chair in Computational Life Sciences and Biology at the University of Texas at Austin, AAAS and APS fellow, former Director of Center for Computational Life Sciences and Biology, he is a leading expert in computer simulations of biomolecular systems and membranes. Prof. Elber’s simulations underpins our understanding of the specificity of MM101 towards cancer cells.
Ron Mittler, PhD
Scientific Co-Founder
Curators’ Distinguished Professor at University of Missouri, AAAS Fellow, a world-renowned expert on reactive oxygen species (ROS) signaling and metabolism, and a leader in the study of biological activity of peptides. Professor Mittler was instrumental in determining the mechanism of action of our lead molecule, MM101.
Assaf Friedler, PhD
Scientific Co-Founder
Professor and Dean of the Faculty of Science, and member of the Institute of Chemistry at the Hebrew University. Assaf is an expert peptide chemist with broad expertise in peptide rational design, synthesis, and peptide-protein interactions.
Mitomed © Copyright. All rights reserved.
We need your consent to load the translations
We use a third-party service to translate the website content that may collect data about your activity. Please review the details in the privacy policy and accept the service to view the translations.